CD274 and cancer: It is believed that a combination of factors, including altered HLA expression, tumor PD-L1 upregulation, somatic mutations with variable neoantigen load, the degree and pattern of the immune infiltration (T-cell exclusion or intratumoral infiltration), all contribute to the observed poor clinical efficacy of ICI in many cancers [23,24].